On November 11, 2025, Shilpa Pharma Lifesciences announced that it has been awarded the highly coveted EcoVadis Gold Medal for its exceptional sustainability performance, making it one of the top-rated pharmaceutical manufacturers not only in Asia but on the global stage. The EcoVadis assessment, which evaluates more than 100,000 companies worldwide, is considered a benchmark for corporate social responsibility, encompassing environmental, labor, ethics, and sustainable procurement criteria.

2025年11月11日，Shilpa Pharma Lifesciences宣布因其卓越的可持续发展表现荣获备受推崇的EcoVadis金奖，成为不仅在亚洲乃至全球范围内评分最高的制药制造商之一。EcoVadis评估涵盖了全球超过10万家企业，被视为企业社会责任的基准，包含环境、劳工、道德和可持续采购标准。

Only the top five percent of evaluated companies receive Gold-level recognition, underscoring Shilpa Pharma Lifesciences' significant achievements in corporate responsibility..

只有排名前百分之五的参评公司获得黄金级认可，凸显了Shilpa Pharma Lifesciences在企业责任方面取得的重大成就。

The EcoVadis rating system is renowned within the B2B pharmaceutical manufacturing sector for its rigorous analysis of a company's sustainable practices. Shilpa Pharma Lifesciences was evaluated across several key areas, including environmental management—such as emissions reduction, waste management, and responsible water usage—social impact, labor conditions, fair business ethics, and sustainable procurement.

EcoVadis评级系统在B2B制药制造领域因其对公司可持续实践的严格分析而闻名。Shilpa Pharma Lifesciences在多个关键领域接受了评估，包括环境管理（如减排、废物管理和负责任的用水）、社会影响、劳动条件、公平商业道德以及可持续采购。

The company established new industry standards by introducing comprehensive environmental management plans, deploying technology-driven waste minimization protocols, and pursuing robust employee skill development programs to ensure worker well-being and company-wide ethical compliance. This recognition will further elevate the company's standing among multinational clients, regulatory authorities, and technology partners across Asia and Europe, reinforcing its commitment to sustainable manufacturing best practices and supply chain excellence..

公司通过引入全面的环境管理计划、部署技术驱动的废物最小化协议，以及推行强有力的员工技能发展计划以确保员工福祉和全公司的道德合规，建立了新的行业标准。这一认可将进一步提升公司在亚洲和欧洲的跨国客户、监管机构和技术合作伙伴中的地位，强化其对可持续制造最佳实践和供应链卓越性的承诺。

The award strengthens Shilpa Pharma Lifesciences' value proposition as a preferred contract development and manufacturing organization (CDMO) for global and regional pharmaceutical brands. Over the last year, the company invested significantly in advanced manufacturing automation, energy-efficient infrastructure, and traceability solutions for raw materials, all in alignment with global environmental, social, and governance (ESG) goals.

该奖项强化了Shilpa Pharma Lifesciences作为全球和地区制药品牌的首选合同开发和制造组织（CDMO）的价值主张。过去一年中，该公司大幅投资于先进的制造自动化、节能基础设施以及原材料的可追溯性解决方案，所有这些均与全球环境、社会和治理（ESG）目标保持一致。

Additionally, Shilpa Pharma Lifesciences has engaged proactively with innovation partners and regional authorities to share best practices for green chemistry, digital transformation in supply chain logistics, and enhanced transparency in supplier qualifications. These measures, supported by the EcoVadis assessment outcomes, illustrate the company's ability to adapt to evolving regulatory frameworks in key Asian markets and its ambition to stay ahead of tightening sustainability requirements across the pharmaceutical industry..

此外，Shilpa Pharma Lifesciences积极与创新合作伙伴和地区当局合作，分享绿色化学、供应链物流数字化转型以及供应商资格认证透明度提升的最佳实践。这些措施得到了EcoVadis评估结果的支持，展示了该公司适应亚洲主要市场不断变化的监管框架的能力，以及其在制药行业日益严格的可持续性要求中保持领先的雄心。

The recognition holds particular significance within the Asian business-to-business pharmaceutical ecosystem, where investor interest, public health authorities, and regulatory scrutiny over sustainability practices continue to increase. Achieving EcoVadis Gold Medal status communicates to stakeholders—including pharma executives, R&D partners, generics manufacturers, and healthcare regulators—that Shilpa Pharma Lifesciences meets and exceeds strict international benchmarks for responsible operations.

在亚洲企业对企业制药生态系统中，这一认可具有特别重要的意义，因为投资者兴趣、公共卫生当局和对可持续实践的监管审查持续增加。获得EcoVadis金奖地位向利益相关者——包括制药业高管、研发合作伙伴、仿制药制造商和医疗监管机构——传达了Shilpa Pharma Lifesciences符合并超越了负责任运营的严格国际基准。

This also positions the company as a knowledge partner for regional industry events and alliances focused on climate risk mitigation, pandemic preparedness, and circular economy initiatives within pharmaceutical production. In the context of a rapidly evolving landscape for ESG reporting and consumer-facing regulations, the Gold Medal acts as both a competitive differentiator and an invitation to potential collaborators seeking alignment with globally validated sustainability leaders..

这也使该公司成为区域行业活动和联盟的知识合作伙伴，这些活动和联盟专注于制药生产中的气候风险缓解、疫情准备和循环经济倡议。在ESG报告和面向消费者的法规快速演变的背景下，金牌既是竞争优势，也是向寻求与全球认可的可持续发展领导者合作的潜在合作者发出的邀请。

Looking ahead, Shilpa Pharma Lifesciences plans to leverage this latest milestone to drive further innovation in sustainable manufacturing, deploy advanced digital tracking for supply chain decarbonization, and expand its partnerships with like-minded organizations and public health agencies. This aligns with broad sectoral trends observed throughout Asia, where pharmaceutical suppliers, active pharmaceutical ingredient (API) manufacturers, and drug product exporters are striving to embrace responsible business standards to enhance international market access.

展望未来，Shilpa Pharma Lifesciences 计划利用这一最新的里程碑，推动可持续制造领域的进一步创新，部署先进的数字追踪以实现供应链脱碳，并扩大与志同道合的组织和公共卫生机构的合作。这与整个亚洲观察到的广泛行业趋势相一致，制药供应商、活性药物成分（API）制造商和药品出口商正努力采用负责任的商业标准，以增强国际市场的准入机会。

With this achievement, Shilpa Pharma Lifesciences not only sets itself apart as a beacon of responsible business practice but also signals its continued readiness to lead the transformation toward a greener, more resilient future for the Asian pharmaceutical industry..

通过这一成就，Shilpa Pharma Lifesciences 不仅将自己树立为负责任商业实践的标杆，还彰显了其持续引领亚洲制药行业向更绿色、更具韧性的未来转型的决心。